🎤Dan Reddy (PhD candidate in the Department of Chemistry at Queen's University and a recipient of the NSERC Vanier Canada Graduate Scholarship. He was recently named one of the top 35 early-career scientists globally in the 2025 CAS Future Leaders program.)In this episode, we interview Daniel Reddy, 2025 CAS Future Leader and PhD candidate at Queen's University, about his groundbreaking research on automated mass spectrometry and dried matrix spots (DMS).Dan's work combines computer vision, 3D printer automation, and laser micromachining to revolutionize sample preparation—reducing CO₂ emissions by 28-fold and organic solvent use by 21-fold compared to traditional methods.<h4>What You'll Learn:</h4><ul><li>How to give a mass spectrometer "sight" and "taste" using computer vision and the LMJ-SSP (Liquid Microjunction Surface Sampling Probe)</li><li>The breakthrough technology behind Surface Energy Traps (SETs) for confining liquid droplets on paper substrates</li><li>Why dried matrix spots eliminate the need for cold-chain shipping and enable analysis of blood, urine, and saliva samples via standard mail</li><li>How DIY chemists are hacking 3D printers to build cost-effective autosamplers (replacing $10K+ systems)</li><li>The role of green chemistry and systems thinking in modernizing analytical methods</li><li>Why interdisciplinary collaboration (chemistry + computer science) is critical to innovation</li></ul><h4>Key Topics:</h4><ul><li>Dried Matrix Spots (DMS) for automated sample prep</li><li>Laser-micromachined Surface Energy Traps</li><li>Direct surface sampling mass spectrometry</li><li>Sustainability in analytical chemistry</li><li>3D printer customization for laboratory automation</li><li>The importance of science communication and community outreach</li></ul><h3>Video Transcription</h3><h4>Introduction</h4>Recent advances in analytical chemistry increasingly focus on simplifying workflows, improving sustainability, and enabling automation. In this context, the work of Dan Reddy centers on the concept of “bringing mass spectrometry to life” through the integration of automated sampling, computer vision, and dried matrix spot (DMS) methodologies.The primary objective is to enable efficient and reproducible analysis of biological and liquid samples—such as blood, urine, saliva, or other solutions—by depositing them onto substrates, drying them, and extracting meaningful analytical information directly via mass spectrometry.<h4>Conceptual Framework: Enabling “Sight” and “Taste” in Mass Spectrometry</h4>A central innovation in this work is the conceptual transformation of mass spectrometry from a passive analytical tool into an active, semi-autonomous system.<ul><li>“Sight” is introduced through camera-based computer vision, allowing the system to identify predefined patterns on a substrate.</li><li>“Taste” is implemented via a liquid microjunction surface sampling probe (LMJSSP), which enables direct extraction of analytes from surfaces.</li></ul>The LMJSSP consists of two concentric capillaries forming a continuously flowing microdroplet. When brought into contact with the sample surface, this droplet facilitates localized extraction, effectively enabling direct surface analysis without traditional chromatographic separation.Combined with an automated positioning system (adapted from 3D printer mechanics), the platform can autonomously locate sampling sites and perform reproducible measurements.<h4>Dried Matrix Spots as an Analytical Platform</h4><h5>Principle and Advantages</h5>Dried matrix spots involve depositing a small volume of liquid sample onto a substrate (commonly paper), followed by drying. This approach offers several advantages:<ul><li>Reduced need for cold-chain transport</li><li>Simplified sample handling and storage</li><li>Compatibility with remote or decentralized sampling</li><li>Lower solvent consumption</li></ul>These features contribute significantly to greener analytical workflows and improved logistical efficiency.<h5>Sustainability Impact</h5>The implementation of DMS-based workflows has demonstrated:<ul><li>Up to 28-fold reduction in CO₂ emissions</li><li>Up to 21-fold reduction in organic solvent use</li></ul>These improvements arise from eliminating cold-chain logistics and minimizing solvent-intensive preparation steps.<h4>Surface Energy Traps (SCTs): Controlled Micro-Sampling Environments</h4><h5>Definition and Fabrication</h5>Surface Energy Traps (SCTs) are microstructured regions on a substrate designed to confine liquid droplets within defined boundaries.The fabrication process involves:<ol><li>Coating paper with a hydrophobic layer</li><li>Using laser ablation to selectively remove the coating in defined patterns</li><li>Creating hydrophilic circular regions (typically ~0.5 mm diameter)</li></ol>These patterned regions act as micro-wells that confine droplets spatially and prevent lateral diffusion.<h5>Analytical Benefits</h5>SCTs address key limitations of traditional dried matrix spots:<ul><li>Improved spatial confinement of analytes</li><li>Reduced diffusion variability</li><li>Enhanced reproducibility</li><li>Preconcentration effects due to controlled drying</li></ul>Additionally, the SCT diameter is smaller than the sampling probe, enabling near-complete analyte collection during surface extraction.<h4>Drying Dynamics and Analyte Distribution</h4>Traditional dried matrix spots often suffer from the “coffee-ring effect”, where analytes redistribute unevenly during drying. This leads to variability depending on sampling location.The SCT approach mitigates these effects by:<ul><li>Limiting diffusion area</li><li>Maintaining analytes near the surface</li><li>Producing more uniform analyte distribution</li></ul>Preliminary investigations (e.g., via SEM imaging) indicate improved homogeneity, although further studies are needed to fully characterize drying kinetics and their influence on signal intensity.<h4>Integration with Automated Sampling Systems</h4><h5>3D Printer-Based Positioning</h5>A key engineering innovation is the repurposing of 3D printer hardware for automated sample positioning:<ul><li>Provides cost-effective XYZ motion control</li><li>Enables programmable sampling routines</li><li>Supports integration with analytical instrumentation</li></ul>Custom software—developed in collaboration with computer engineers—allows users to define coordinates, dwell times, and sampling parameters.<h5>Computer Vision Integration</h5>The addition of computer vision enables:<ul><li>Pattern recognition (e.g., alignment markers near SCTs)</li><li>Autonomous targeting of sampling locations</li><li>Reduced operator intervention</li></ul>This transforms the system into a semi-autonomous analytical platform.<h4>Comparison with Conventional Workflows</h4>Compared to traditional LC-MS or GC-MS workflows, the presented approach offers:<div><div><figure class="table"><table><thead><tr><th>Aspect</th><th>Conventional Methods</th><th>SCT + LMJSSP Approach</th></tr></thead><tbody><tr><td>Sample prep</td><td>Multi-step, solvent-intensive</td><td>Minimal, direct surface sampling</td></tr><tr><td>Chromatography</td><td>Required</td><td>Potentially bypassed</td></tr><tr><td>Throughput</td><td>Moderate</td><td>High (automated)</td></tr><tr><td>Sustainability</td><td>Limited</td><td>Significantly improved</td></tr></tbody></table></figure></div></div>While chromatographic methods remain essential for many applications, this approach provides a complementary pathway for rapid screening and targeted analyses.<h4>Green Chemistry and Systems Thinking</h4>A notable aspect of this work is the integration of systems thinking into analytical chemistry. Inspired by engagement with organizations such as the American Chemical Society and green chemistry initiatives, the research emphasizes:<ul><li>Environmental impact reduction</li><li>Resource efficiency</li><li>Lifecycle considerations</li></ul>This perspective expands the role of analytical chemists beyond method performance to broader societal and environmental implications.<h4>Future Outlook and Applications</h4>The research is currently at an early stage but shows strong potential for:<ul><li>Decentralized diagnostics (e.g., remote blood sampling)</li><li>Environmental monitoring</li><li>High-throughput screening workflows</li><li>Field-deployable analytical systems</li></ul>Further advancements are expected in:<ul><li>Substrate engineering</li><li>Automation robustness</li><li>Integration with advanced MS platforms (e.g., triple quadrupole systems)</li></ul><h4>Conclusion</h4>The integration of dried matrix spots, surface energy traps, and automated surface sampling represents a significant step toward more sustainable, efficient, and accessible analytical workflows.By combining innovations in microfabrication, computer vision, and mass spectrometry, the work of Dan Reddy demonstrates how analytical chemistry can evolve toward smarter, greener, and more autonomous systems.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

Mass Spectrometry, Surface Sampling and Dried Matrix Spots - Greener Chemistry and 3D Printing

This study presents a novel MS/MS filtering tree approach for distinguishing regio- and stereoisomeric bile acids in untargeted LC-MS/MS data. By leveraging intensity ratios of closely related fragment ions, the method overcomes limitations of traditional spectral matching, enabling more accurate isomer annotation.A user-friendly web-based application was developed to facilitate implementation without coding expertise. Applied to public datasets, the workflow revealed diet-associated bile acid patterns across mammalian species and enabled identification of previously uncharacterized compounds, demonstrating its potential for large-scale metabolomics studies.<blockquote><h4>The original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677">MS/MS Mass Spectrometry Filtering Tree for Bile Acid Regio- and Stereoisomer Annotation</a></h4>Ipsita Mohanty, Shipei Xing, Vanessa Castillo, Julius Agongo, Abubaker Patan, Yasin El Abiead, Helena Mannochio-Russo, Wilhan D. Gonçalves Nunes, Jasmine Zemlin, Itzhak Mizrahi, Dionicio Siegel, Mingxun Wang, Lee R. Hagey, and Pieter C. Dorrestein*Anal. Chem. 2026, 98, 6, 4571–4584<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1021/acs.analchem.5c05677">https://doi.org/10.1021/acs.analchem.5c05677</a><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.<div>Cholesterol-derived steroid molecules, known as bile acids, have been detected in nearly every organ where they have been studied. <a href="javascript:void(0);">(1)</a> Alterations in bile acid composition and dysbiosis have been linked to various health conditions, including neurocognitive developmental disorders, cancer, infections, and metabolic diseases such as diabetes and inflammatory bowel disease (IBD). <a href="javascript:void(0);">(2−8)</a> In the last 5 years, the number of detected bile acids in metabolomics experiments <a href="javascript:void(0);">(1,9−15)</a> has increased by the 1000s and possibly approaching 10,000s - most of which have not yet been fully structurally characterized. <a href="javascript:void(0);">(1,6,16−19)</a> We believe this is only the tip of the iceberg and that in the next 5 years this number will continue to increase. The scale of the bile acid pool and the challenge of accurately detecting and describing their structure truly represent an exciting frontier for analytical and computational scientists who continue to push the boundaries of what is possible.In humans, bile acids are predominantly derived from cholesterol through pathways that exist not only in the liver as previously thought but also in many other organs including kidneys and brain. <a href="javascript:void(0);">(16,20,21)</a> These pathways shorten the side chain, producing a carboxyl terminus on the remaining 24-carbon steroid structure, which consists of four interconnected rings and side chain, collectively referred to here as the “core” (colored in <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig1">Figure 1</a>a). The core of bile acids undergoes multiple hydroxylations, a process typically associated with the liver but also occurring in other organs such as the brain, kidney, and spleen. <a href="javascript:void(0);">(16)</a> Considering hydroxylation at known carbon positions on bile acids reported from human samples (as starred in <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig1">Figure 1</a>a, <a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c05677/suppl_file/ac5c05677_si_002.xlsx">Supplementary Table S1</a>) along with stereoisomers and allo versus nonallo A/B ring isomerization at C5, approximately 1,800 candidate mono-, di-, and trihydroxy C24 bile acid cores are theoretically possible (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig1">Figure 1</a>a). This number further expands exponentially in the gut.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2026_98_6_4571_4584_Figure_1_MS_MS_fragmentation_of_bile_acid_isomers_9bfcc8779d.jpg" alt="Anal. Chem. 2026, 98, 6, 4571–4584: Figure 1. MS/MS fragmentation of bile acid isomers. (a) Structure of bile acids highlighting mono-, di-, and trihydroxylated steroid cores, with experimentally observed potential hydroxylation sites on the steroid core indicated by red stars. (b) MS/MS fragmentation spectra of the regioisomers, taurochenodeoxycholic (TCDCA) acid and taurodeoxycholic acid (TDCA), illustrating a low-intensity mass region containing ions unique to each isomer. (c) Enlarged view of the MS/MS fragmentation spectra for taurochenodeoxycholic and taurodeoxycholic acids, emphasizing the ion pair used to calculate relative intensity ratios for differentiating these isomers." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2026_98_6_4571_4584_Figure_1_MS_MS_fragmentation_of_bile_acid_isomers_9bfcc8779d.jpg 245w," sizes="100vw" width="2100" height="890">Recently, we developed MS/MS fragmentation-based filters using a Mass Spectrometry Query Language (MassQL), a query language that allows filtering of data patterns <a href="javascript:void(0);">(49)</a> to retrieve all MS/MS spectra from the Orbitrap data sets in GNPS/MassIVE repository containing bile acid-specific fragment ions. After merging similar spectra, this resulted in a reference library of 21,549 MS/MS spectra. <a href="javascript:void(0);">(1)</a> This library includes MS/MS spectra of known and many yet-to-be structurally characterized bile acid candidates that have already been detected from public metabolomics data repositories. This also includes MS/MS of multiple ion forms such as different adducts, in-source fragments, and multimers, <a href="javascript:void(0);">(1)</a> which all help in the annotation of bile acids. This MassQL library enables the annotation of the number of hydroxyl groups on the bile acid core, as well as the identification of potential modifications, and ∼ 62% of the atomic compositions are annotated. Other spectral “modifications” that do not have a distinct atomic composition may be different adducts or multiple combinations of adducts, in source fragments, and multimers. However, the diagnostic bile acid MS/MS fragments used to build this reference library do not allow for the differentiation between regio- and stereoisomers. Also, MS/MS spectral matching with the candidate library using the cosine metric often overlooks finer details within fragment ions, as minor peak intensity changes or low-intensity fragment ions have a minimal influence on overall spectral match scores (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig1">Figure 1</a>b).Based on our manual inspection of hundreds of bile acid MS/MS spectra, we observed and hypothesized that information in the low-intensity MS/MS fragments, including specific ion pairs, their intensity ratios, and unique ions, could be used to distinguish the steroid core isomers. As proof of concept in leveraging MS/MS data to enable further refinement of the stereo and regiochemistry of the hydroxylations of the bile acids cores, we developed a MassQL-based filtering tree utilizing key marker ions and their intensity ratios within narrow m/z windows to propose regio- and stereoisomer assignments of bile acids solely from MS/MS data. In this study, we focus on bile acid amidates, a class of structures found in humans and other animals.<h4>Experimental Section</h4><h5>MS/MS Data Acquisition of Taurine-Conjugated Bile Acids</h5>We generated one mM stock solutions of our in-house collection of 48 taurine-conjugated bile acids in 100% MeOH. The standards used in this study were obtained from the bile acid collection of the late Dr. Alan Hofmann’s laboratory at UCSD. The Dorrestein laboratory inherited these standards after his demise. The standard samples were injected (5 μL) into a Vanquish ultrahigh-performance liquid chromatography (UHPLC) system coupled to a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/559">Q-Exactive quadrupole Orbitrap mass spectrometer</a> (Thermo Fisher Scientific, Waltham, MA). A <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1509">Kinetex polar C18 column</a> (2.1 × 100 mm, 2.6 μm particle size, 100 A pore size; Phenomenex, Torrance) was employed with a SecurityGuard C18 column (2.1 mm ID) at 40 °C column temperature. The mobile phases (0.5 mL/min) were 0.1% formic acid in both water (A) and ACN (B) with the following gradient: 0–0.5 min 5%B, 0.5–1.1 min 5–25%B, 1.1–7.5 min 25–40%B, 7.5–8.5 min 40–99%B, 8.5–10 min 99%B, 10–12 min 5%B. The mass spectrometer was operated in positive heated electrospray ionization with the following parameters: sheath gas flow, 53 AU; auxiliary gas flow, 14 AU; sweep gas flow, 3 AU; auxiliary gas temperature, 400 °C; spray voltage, 3.5 kV; inlet capillary temperature, 269 °C; S-lens level, 50 V. MS1 scan was performed at m/z 150–1500 with the following parameters: resolution, 35,000 at m/z 200; maximum ion injection time, 100 ms; automatic gain control (AGC) target, 1E6. Up to 5 MS/MS spectra per MS1 scan were recorded under the data-dependent mode (dd-MS2) with the following parameters: resolution, 17,500 at m/z 200; maximum ion injection time, 150 ms; AGC target, 5.0E5; MS/MS precursor isolation window, m/z 1; isolation offset, m/z 0.5; normalized collision energy (NCE) of 45%; minimum AGC for MS/MS spectrum, 2.5E4; apex trigger, 2 to 5 s; dynamic precursor exclusion, 8 s. Fragmentation was performed in the HCD cell using nitrogen as the collision gas. The data was deposited in GNPS/MassIVE and is publicly available at MSV000092003. The MS/MS spectra are also added now to the GNPS spectral library - BILELIB19 (<a target="_blank" rel="noopener noreferrer" href="https://gnps.ucsd.edu/ProteoSAFe/gnpslibrary.jsp?library=BILELIB19">https://gnps.ucsd.edu/ProteoSAFe/gnpslibrary.jsp?library=BILELIB19</a>)<h4>Results and Discussion</h4><h5>Retrospective Bile Acid Isomer Profiling in a Public Data Set of Animals with Different Diets</h5>To illustrate the utility of the MassQL multistep filtering trees in retrospectively analyzing data in public repositories, we selected a publicly available data set containing feces from 40 animals (13 mammalian species) from the Zoological Center Tel Aviv-Ramat Gan, Israel. <a href="javascript:void(0);">(62)</a> The data set consisted of 3 herbivores, 23 omnivores, and 13 carnivores (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig4">Figure 4</a>a). We selected this data set as we had previously confirmed detection of 6 previously uncharacterized polyamine-conjugated bile acids that we could not confirm with retention times as none of the standards we had synthesized matched, although their MS/MS did. We showed that their levels were higher in carnivores compared to herbivores and omnivores; <a href="javascript:void(0);">(1)</a> however, we were still unable to resolve the regio- and stereochemistry of all possible isomers of polyamine-conjugated bile acids. To further dive into the diversity of bile acids, we matched the MS/MS spectra of this study against the GNPS spectral libraries, including the candidate bile acid MS/MS reference library that we had previously created from the repository scale analysis. <a href="javascript:void(0);">(1)</a> This revealed 993 MS/MS spectral matches to bile acids. We next applied the multistep MassQL queries to resolve the regio- and stereochemistry of the bile acids. The steps described in this section follow the same filtering approach as outlined for the dihydroxy bile acid filtering tree (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig2">Figure 2</a>).&nbsp;<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2026_98_6_4571_4584_Figure_2_Development_of_MSMS_fragmentation_based_Mass_QL_filtering_tree_2227b688a9.jpg" alt="Anal. Chem. 2026, 98, 6, 4571–4584: Figure 2. Development of MS/MS fragmentation-based MassQL filtering tree. Sequential MS/MS fragmentation-based filtering tree designed to classify regio- and stereoisomers of dihydroxylated bile acids. Structures at each filtering step are shown, with terminal bins color-coded for clarity." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2026_98_6_4571_4584_Figure_2_Development_of_MSMS_fragmentation_based_Mass_QL_filtering_tree_2227b688a9.jpg 183w," sizes="100vw" width="1000" height="852">Step 1 excludes MS/MS spectral matches to candidate bile acids where the experimental spectra lacked the two diagnostic MS/MS ions for bile acids. Steroids and lipids often exhibit similar MS/MS spectra to bile acids, sometimes yielding high cosine similarity scores (&gt;0.7), yet they lack key low-intensity diagnostic ions. Due to the low intensity of these ions, their presence or absence typically does not significantly affect spectral matching scores. However, our MassQL isomer filters in Step 1 identified these MS/MS spectra to reveal that 543 MS/MS spectra had the two characteristic fragment ions for mono-, di-, and trihydroxy bile acids (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig4">Figure 4</a>a). A portion of the 543 MS/MS spectra are adducts, in-source fragments, and multimers, overall reducing the number of unique bile acid structures. Based on retention time and peak shape correlation analysis in MZmine4, <a href="javascript:void(0);">(63)</a> a strategy that allows the discovery of ion forms associated with a specific molecule, we estimate these to represent 402 bile acids. Even though the data contained evidence for hundreds of unique bile acids, the stereo- and regiochemistry of hydroxylations were yet to be defined.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Anal_Chem_2026_98_6_4571_4584_Figure_4_Filtering_of_bile_acid_isomers_in_an_untargeted_LC_MS_MS_data_set_d7f119b028.jpg" alt="Anal. Chem. 2026, 98, 6, 4571–4584: Figure 4. Filtering of bile acid isomers in an untargeted LC-MS/MS data set. Representative example for using the MassQL filters for identifying bile acid isomers. (a) Overview of study design. Fecal samples from herbivores (n = 3), omnivores (n = 23), and carnivores (n = 13) were analyzed by LC-MS/MS and processed using MZmine4 and FBMN on GNPS2. Stepwise MassQL filtering refined candidate bile acids from 543 features (Step 1) to 96 (Steps 2 and 3) and 49 stereo and regiochemistry assigned MS/MS spectra (Step 4). Differential abundance of bile acids between herbivores/omnivores and carnivores is illustrated in the volcano plots (b) at Step 1 and (c) Step 4 of the dihydroxy filtering tree. The annotation of a previously uncharacterized bile acid was refined from (OH)2-N-acetyl-putrescine to 3,12α-N-acetyl-putrescine." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Anal_Chem_2026_98_6_4571_4584_Figure_4_Filtering_of_bile_acid_isomers_in_an_untargeted_LC_MS_MS_data_set_d7f119b028.jpg 243w," sizes="100vw" width="1819" height="1170">The application of our MassQL filtering tree allowed us to further refine structural details within the bile acid core. After Step 2 and Step 3 of the MassQL filtering, we separated the amidated mono-, di-, and trihydroxylated bile acids from their ketones and unconjugated versions to give 96 bile acids (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig4">Figure 4</a>a). A univariate analysis at Step 1 of bile acid annotations showed a higher abundance of almost all bile acids in the carnivores compared to herbivores and omnivores combined (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig4">Figure 4</a>b). As we move down the MassQL filtering tree to Step 4, we can now hypothesize the regio- and, in many cases, the stereochemistry of their hydroxyl positions. With the current implementation of the tree, we can predict the bile acid cores of 49 MS/MS spectra (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig4">Figure 4</a>a). The highest number of spectral matches that could be assigned are dihydroxylated bile acids, symbolized here as (OH)2 (<a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c05677#fig4">Figure 4</a>c). These were categorized into individual bins of 3,12α-(OH)2, 3,7-(OH)2; 3,6-(OH)2; 3,12β-(OH)2; 7,12β-(OH)2 and 3,6-(OH)2 isomers following the application of the dihydroxy isomer filtering tree.<h4>Conclusion</h4>In conclusion, this study introduces the concept of using a MassQL MS/MS fragmentation-based filtering tree approach to enable precise regio- and stereochemical differentiation of bile acid isomers, which were subsequently validated against reference standards. The method expands the ability to annotate bile acids and has led to the discovery of bile acid deoxycholyl-N-acetyl-putrescine, which had previously been detected in the feces of carnivores but not structurally characterized. By making annotated MS/MS spectra publicly available and enabling the MassQL queries, this approach enhances bile acid analysis, offering innovative tools for exploring their metabolic roles and biological significance, including retro-analysis of regio- and stereochemical isomer variations in existing public LC-MS/MS data.</div>

MS/MS Mass Spectrometry Filtering Tree for Bile Acid Regio- and Stereoisomer Annotation

In the week of April 6, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars">👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</a></h4>👉 Search and filter in the largest global database with over 5 500 GC, LC, MS and spectroscopy webinars.</blockquote><h5>1. Waters Corporation: Fit-for-purpose workflows for inositol stereoisomer profiling in dietary supplements and foods using single and tandem mass spectrometry</h5><ul><li>Tu, 7.4.2026 19:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6030">Registration</a></li></ul>The aim of this webinar is to present analytical procedures capable of simultaneously separating and quantifying free inositol stereoisomers in both simple matrices and complex matrices.<h5>2. Thermo Fisher Scientific: Transforming Fuel Testing Performance with Combustion Ion Chromatography</h5><ul><li>We, 8.4.2026 07:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6093">Registration</a></li></ul>Join us for an interactive session on how Combustion Ion Chromatography (C-IC) is transforming fuel testing performance in modern laboratories.<h5>3. SCIEX: Getting started with LC-MS/MS for PFAS</h5><ul><li>We, 8.4.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6102">Registration</a></li></ul>Learn how to build LC-MS/MS methods for PFAS analysis, achieve ultra-low detection limits, and gain practical skills for environmental and food testing in this expert-led webinar.<h5>4. Phenomenex: Extraction Face-Off: Choosing Between SLE and SPE</h5><ul><li>We, 8.4.2026 10:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6092">Registration</a></li></ul>Understand how SLE and SPE work and how they are different from each other.<h5>5. Waters Corporation: RADIAN™ ASAP Mass Spectrometry for the Detection and Analysis of Explosive Traces</h5><ul><li>We, 8.4.2026 16:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6031">Registration</a></li></ul>Explore how mass spectrometry enables rapid detection of trace explosives. Learn how RADIAN™ ASAP extends forensic and security workflows, supporting future screening technologies and ion-mobility innovation.<h5>6. Technology Networks: Label Free Quantitation: New Insights Into High-Throughput Proteomic Workflows</h5><ul><li>Th, 9.4.2026 16:00 CET</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/5969">Registration</a></li></ul>Discover how next-generation LC–MS and the ZenoTOF 8600 enable robust, high-throughput LFQ proteomics, backed by insights from a large multi-laboratory benchmark study.

Webinars LabRulezLCMS Week 15/2026

Article

Webinars

Video

Scientists

Scientific article

Interview

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Agilent Technologies

Technology Networks

Phenomenex

Thermo Fisher Scientific

Waters Corporation

This webinar is about single quad mass detectors. We will look at the development of single quads together and highlight the possibilities offered by today's single quads and how they support the user.The aim of the webinar is to show users how they can easily add mass-selective confirmation to their HPLC-UV methods. In other words: achieve greater security without more complexity.<blockquote>Presenter: Shaun Pritchard (Product Specialist Liquid Phase Separations, Agilent Technologies)Shaun Pritchard is a Product Specialist for separation products at Agilent Technologies covering the UK and Ireland. He started his career in 1989 working at a large Pharmaceutical company holding a number of roles, this is where he became passionate about HPLC finally in 1998 he took the leap to leave the lab and move to the commercial side of things and has had a number of roles within the industry until 2017 he joined Agilent.</blockquote>

Agilent Technologies: HPLC Beginner Webinar Series

Single Quad mass detection for Chromatographers

We will look at the development of single quads together and highlight the possibilities offered by today's single quads and how they support the user.

In this webinar, we will present several case studies of how different light scattering techniques can be used for advanced characterization of biopharmaceutical samples.In particular, we will focus on dynamic light scattering (DLS), size-exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) and real-time multi-angle light scattering (RT-MALS).<h4>Key Takeaways:</h4><ul><li>Learn basics of light scattering techniques &nbsp;</li><li>Distinguish between different light scattering methods – DLS, SLS, SEC-MALS, RT-MALS &nbsp;</li><li>Understand how different light scattering can be used to characterize therapeutic proteins</li></ul><h4>Who should attend:</h4><ul><li>Scientists interested in analytical characterization of biopharmaceuticals using light scattering techniques.</li></ul><blockquote>Presenter: Hristo L. Svilenov, Ph.D. (Ghent University)Dr. Svilenov is an Associate Professor in Biopharmaceutical Technology. His research interests are in the development, formulation and manufacturing aspects of biotherapeutics. Previously, Dr. Svilenov was a postdoctoral researcher funded by a Peter and Traudl Engelhorn Fellowship at the TU Munich. From 2016 to 2019, Dr. Svilenov did his PhD supported by a Marie Sklodowska-Curie Fellowship at the Ludwig Maximilian University of Munich. He defended his doctoral thesis with the highest distinctions in Germany (summa cum laude) and received the AbbVie prize and the Carl-Wilhelm-Scheele of the German Pharmaceutical Society for his work.Presenter:&nbsp;Lorenzo Gentiluomo, Ph.D. (Waters | Wyatt Technology)Lorenzo Gentiluomo, Ph.D. in Pharmaceutical Technology and currently concluding an Executive MBA, has several years of experience in drug product development. He has successfully managed the development of 26 biological drug candidates, including 3 BLA projects, during his tenure at Coriolis and Lonza. Lorenzo now serves as Senior Account Sales Manager for Wyatt Technology, overseeing the portfolio in Switzerland, where he applies his deep technical expertise to support and expand the use of advanced analytical solutions in the biopharmaceutical industry.</blockquote>

Waters Corporation: Leveraging light scattering techniques for enhanced biotherapeutic characterization and development

Leveraging light scattering techniques for enhanced biotherapeutic characterization and development

How different light scattering techniques can be used for advanced characterization of biopharmaceutical samples.

Leveraging light scattering techniques

<h4>Key Learning Points:</h4><ul><li>Identify the common challenges associated with solid phase extraction methods &nbsp;</li><li>Understand and troubleshoot the recovery, contamination and reproducibility issues &nbsp;</li><li>Learn how to find and apply solutions to develop robust and reproducible extraction methods for their sample preparation needs</li></ul><h4>Who Should Attend:</h4><ul><li>Any scientists who wants to learn about solid phase extraction and it’s associated challenges, common troubleshooting steps and solutions to develop robust and reproducible extraction methods for their sample preparation needs</li></ul><blockquote>Presnter: Namrata Saxena (Technical Manager, Phenomenex)Namrata is the Technical Manager for the Asia-Pacific region in Phenomenex and is based in Sydney, Australia. As a member of the global technical team, she is responsible for assisting external customers as well as internal marketing and sales teams of Phenomenex for multifarious technical queries. She specifically support company’s bio-products portfolio through external and internal seminars/webinars, trainings and also contribute in biologics related technical content creation.Before joining Phenomenex she had worked as a Product Specialist and spent several years in stationary phase chemistry, column manufacturing and method development groups in a German company Bischoff Chromatography GmbH.Namrata has a post graduate degree with specialization in Analytical Chemistry. Her competence and focus lies in biotherapeutics characterization through liquid chromatography, antibodies and oligonucleotide chemistry, gene therapy and new bio-therapeutic modalities.</blockquote>

Phenomenex: Solid Phase Extraction Troubleshooting Tips and Tricks

Solid Phase Extraction Troubleshooting Tips and Tricks

Identify the common challenges associated with solid phase extraction methods.

Our guest speakers will discuss automation within their lab and how the Andrew+ liquid handling robot has helped streamline their sample preparation workflows for proteomic analysis.Automation is fast becoming a priority for labs who are looking to improve liquid handling pipetting procedures for simple, yet critical, protocols. The automation of liquid handling procedures allows labs to streamline workflows, helping to improve.<ul><li>Reproducibility - Laboratory automation eliminates most human errors resulting in more reliable data and improved productivity.</li><li>Productivity - Andrew+ combines the flexibility of single channel pipetting (0.2 μL to 10 mL) with the higher throughput of multichannel pipetting.</li><li>Health in the Lab - Pipetting requires repetitive movements (of up to 500 times per day for the average user) that can lead to Musculo-skeletal disorders like repetitive strain injury. The use of automated liquid handling reliefs users from this high throughput pipetting burden, helping to improve health within the lab setting.</li></ul><h4>Testimonials from our guest speakers</h4><h5>Dr Harry Whitwell, Imperial College London</h5>Andrew+ has been a huge asset to the group and is used continuously to support routine sample prep from protein assay to digestion, desalting, peptide assay, sample-standardisation, plate formatting and study reference generation, helping to substantially minimise batch-variation. Data from repeated dilution series across months shows excellent reproducibility in pipetting accuracy and stability with inter-assay CV &lt;5% and R2 above 0.99.<h5>Dr Pavel Shliaha, MRC</h5>In our lab, we use automation in attention-heavy workflows, e.g. concentration normalisation and SPE. The main workflows that we are using the Andrew+ is for concentration normalisation for proteomics. We also plan to use it for SPE for proteomics. My favourite things about the Andrew+ robot are as follows: user interface, great technical support, ability to easily switch pipettes, without the necessity for calibration.<h5>Dr Colleen Maxwell, University of Leicester</h5>We previously found it a major challenge to find sample preparation solutions to match the large scale required for our large cohort clinical proteomics studies without compromising on flexibility – we used to rely on laborious protocols requiring manual pipetting steps in small batches, we have found that these are no longer suitable, and are likely to introduce unwanted batch effects over the long term. Andrew+ has revolutionised our workflows, offering versatility beyond standard bottom-up proteomics digestion and clean-up. Andrew+ is such an adaptable system, so has had a transformative impact on all aspects of experimental design, and has been adopted throughout all our bottom-up proteomics workflows at the van Geest Multiomics Facility in the University of Leicester.<blockquote>Presenter:&nbsp;Dr Harry Whitwell (Lecturer and Proteomics Platform Lead, Imperial College London)Dr Harry Whitwell has been proteomic lead at the National Phenome Centre at Imperial College London since June 2020. Alongside this position, he was appointed Lecturer in Proteomics and Integrative Data Analysis in October 2023. Building on funding MRC, EPSRC and BBSRC, he has established a far-reaching facility, supporting projects across the UK. His research focuses on combining multiple analytical modalities to understand disease including mass spec-imaging, proteomics and network-based data analysis techniques.Presenter:&nbsp;Dr Pavel Shliaha (Head of Proteomics and Metabolomics, MRC, Laboratory of Medical Sciences)Dr Pavel Shliaha completed his Ph.D. in proteomics at the laboratory of Professor Kathryn Lilley in Cambridge, UK, focusing on organelle proteomics. He then pursued a postdoctoral project in Professor Ole Jensen's group at the University of Southern Denmark, concentrating on histone PTM profiling and intact protein analysis. Pavel briefly worked at Memorial Sloan Kettering Cancer Center as a postdoc before moving to MSD (New Jersey). Throughout his career, Pavel has been interested in automation and high-throughput sample processing. In particular, he has experience working with Hamilton Star, Opentrons, and Andrew+ systems.Presenter: Dr Colleen Maxwell (Postdoctoral Researcher, University of Leicester)Colleen is a post-doctoral research associate at the Leicester van Geest Multiomics Facility at the University of Leicester. She completed her undergraduate studies in Chemistry at Imperial College London, graduating in 2019. During this time, she spent a year working in a pharmaceutical company, where she gained her initial exposure to analytical chemistry and mass spectrometry. Motivated by her interest in this field, Colleen pursued a PhD at the University of Leicester, focusing on the use of shotgun and targeted proteomics to develop and validate multiplexed biomarker panels for coronary artery disease. After completing her PhD in 2023, she continued her research as a postdoctoral associate, expanding her work to include new projects that integrate deep cardiac MRI phenotyping with proteomics in collaboration with the cardiac imaging team at Leicester. Colleen is passionate about the automation and standardisation of proteomics to ensure highly reproducible and high-throughput biomarker studies in large clinical cohorts</blockquote>

Waters Corporation: Streamlined Proteomics with the Power of Andrew+

Streamlined Proteomics with the Power of Andrew+

How the Andrew+ liquid handling robot has helped streamline their sample preparation workflows for proteomic analysis.

This webinar will guide you through optimizing your Q-TOF for superior data quality by selecting the most suitable tune mode for your samples.We will delve into various MS acquisition modes, including MS only, All Ions (QRAI), Auto MS/MS (directed MS/MS; targeted MS/MS), and PRM mode.Learn how to fine-tune method settings to enhance your data quality and achieve the best analytical results. Whether you’re a seasoned user or new to QTOF, this session will provide valuable insights to elevate your mass spectrometry.<blockquote>Presenter: &nbsp;Stefan Schaebler (Application Specialist LC/MS, Agilent Technologies)Stefan completed his PhD in Biology, specializing in LC-MS-based lipidomics and metabolomics. Following his doctoral studies, he joined Agilent Technologies as an LC/MS Application Specialist. In this role, Stefan focuses on small molecule applications using LC-QTOF, with a strong emphasis on software tools and data interpretation.</blockquote>

Agilent Technologies: MassHunter Masterclass Months

MassHunter Acquisition Q-TOF Part II – Advance Settings

Join us for an in-depth exploration of advanced settings in MassHunter Acquisition for Q-TOF systems.

Novel biotherapeutics, including bispecific and multispecific antibodies (bsAb, msAb), antibody-drug conjugates (ADCs), and antibody-oligonucleotide conjugates (AOCs), are revolutionizing biomedical therapies yet pose analytical challenges due to their sequence diversity, structural complexity, and susceptibility to various degradation pathways.In this presentation, Ben Niu will showcase how his team has integrated advanced techniques such as automation and machine learning to achieve unprecedented mass spectrometry-focused sample handling capabilities and rapid turnover rates. These approaches deliver unmatched depth and breadth in understanding diverse molecular modalities within a condensed timeline.Who should attend?Scientists who develop novel biotherapeuticsWhat You Will Learn?Overcoming analytical challenges relating to the development of novel biotherapeutics, via utilization of automation and machine learning to achieve unprecedented mass spectrometry-focused sample handling capabilities and rapid turnover rates.<blockquote>Presenter: Ben Niu, PhD (Principal Scientist, Discovery Biotherapeutics, Bristol Myers Squibb)Ben Niu is a Principal Scientist at Bristol Myers Squibb (BMS), leading a pioneering mass spectrometry team within the Discovery Biotherapeutics department. With over seven years of experience in the biopharmaceutical industry, Ben specializes in analytical characterization, particularly in mass spectrometry techniques, driving critical insights for drug development. He champions the integration of automation and machine learning to revolutionize analytical workflows.Presenter: Dr. Kelly Broster (Sr Manager, Market Development &amp; Collaborations, Pharma Biopharma, Thermo Fisher Scientific)</blockquote>

Thermo Fisher Scientific: High-throughput and automation in novel modalities (msAbs, ADCs, AOCs) screening, characterization, and beyond

High-throughput and automation in novel modalities (msAbs, ADCs, AOCs) screening, characterization, and beyond

Integrated advanced techniques to achieve unprecedented mass spectrometry-focused sample handling capabilities and rapid turnover rates

Automation in novel modalities (msAbs, ADCs, AOCs) screening

As the therapeutic potential of RNA expands beyond COVID vaccines, new mRNA drug candidates for personalized cancer treatments and CRISPR sgRNA complexes are emerging, offering solutions for genetic disorders and epigenetic modulation. Recent advancements in RNA analysis provide critical insights into drug design, stability, purity, and molecular integrity. To analyze larger therapeutic RNAs by LC-MS, they must be broken down into smaller fragments. Novel RNA endonucleases, high-purity mobile phase reagents, and integrated data processing workflows now simplify and automate these tasks, making LC-MS assays more accessible. These innovations lower the adoption barrier for LC-MS, accelerating the development and market readiness of RNA-based therapeutics. Waters is at the forefront of advancing RNA therapy development with innovative analytical tools and workflows designed for rapid and precise sequence confirmation and modification mapping. This webinar will feature insights from Quality Assistance a leading European Contract Research Organisation (CRO) offering a range of services including mRNA and CRISPR sgRNA testing. In this discussion, Quality Assistance will highlight their implementation of Waters' latest RNA solutions and discuss the analytical benefits these new tools have provided. &nbsp;In this webinar you will learn: <ul><li>A comprehensive set of tools for LC-MS analysis of large RNA molecules, including enzymes, reagents, and informatics tools</li><li>Novel digestion protocols with new RNases for identity, purity, and modification mapping</li><li>Method considerations for sgRNA and mRNA digestion and data analysis</li></ul><blockquote>Presenter: Dr. Thomas Menneteau (R&amp;D Scientist, Quality Assistance)Dr. Thomas Menneteau studied at the Université Paul Sabatier in Toulouse, France and defended his thesis on the characterization of proteasome complexes by mass spectrometry in Dr Schiltz lab. He joined Dr. Thalassinos &amp; Prof. Tabrizi labs at University College London as a postdoc to study DNA repair complexes involved in Huntington disease by native mass spectrometry and crosslinking-MS. He joined Quality Assistance in 2021 as a R&amp;D Scientist and he is involved in the development of LC-MS method for the analysis of biomolecules (proteins, mRNA, …).Presenter: Christian Reidy (Principal Product Manager, Waters Corporation)Christian Reidy is a Principal Product Manager at Waters Corporation, specializing in analytical solutions for cell and gene therapy applications including HILIC, AEX, novel enzymes, standards, and reagents. With over a decade of experience in analytical chemistry, including project management and chemistry account management, Christian supports the advancement and commercialization of innovative products that empower researchers and pharmaceutical companies to advance RNA development.</blockquote>

Waters: Analyzing mRNA and sgRNA with Advanced Enzymes, Mass Spectrometry, and Informatics

Analyzing mRNA and sgRNA with Advanced Enzymes, Mass Spectrometry, and Informatics

Analyzing mRNA and sgRNA

Measurement of FT4 and FT3 is typically performed by immunoassay, however these can be prone to suffer from interferences and a lack of selectivity. Currently, the accepted gold standard for the measurement of FT4 and FT3 is using equilibrium dialysis (ED) and combined with the use of LC-MS/MS can overcome the issues with immunoassay in the measurement of FT4 and FT3. However, the equilibrium dialysis procedure can be quite time consuming and often being performed overnight.Here, we describe a simple clinical research method to perform ED using a commercially available device followed by sample preparation by solid phase extraction (SPE) and UPLC-MS/MS analysis using the Waters™ ACQUITY™ UPLC and analytically sensitive Xevo™ TQ Absolute Mass Spectrometer for clinical research. Data analysis and review has been simplified with the use of the waters_connect™ with QUAN Review Software. This has allowed for the complete workflow including equilibrium dialysis to be performed within a typical working day.Simplified Equilibrium Dialysis for the UPLC-MS/MS Analysis of Free Testosterone (FT) for Clinical ResearchHistorically, the measurement of free testosterone in human serum has presented a challenge for laboratory scientists, with such a large portion bound and the complexity and time involved in “gold standard” equilibrium dialysis. With a simple, fast, workflow combined with the analytical sensitivity afforded by the Waters Xevo™ TQ Absolute Mass Spectrometer, a newly developed, precise, accurate and selective clinical research method will be presented.<blockquote>Presenter: Robert Wardle (Senior Clinical Scientist, Waters Corporation)Robert Wardle is currently a Senior Scientist employed at Waters Corporation in Wilmslow, UK, performing research and development of applications and products for Clinical Research. His primary area of research is vitamins and in particular vitamin D metabolites, steroid hormones and in-depth knowledge of offline and online automation.Robert joined Waters in 2010 as a Clinical Validation Scientist, playing a key role in verification activities for the MassTrak XE Immunosuppressants kit available in the EU. He moved into his current role as a Senior Scientist in 2013, where he developed clinical research methods for a range of applications including vitamin D metabolites, estrogens, a large panel of steroid hormones and more recently this application on free T4 and free T3.Presenter: Stephen Balloch (Senior Clinical Scientist, Waters Corporation)Stephen Balloch graduated from the University of York (UK) with a Master’s degree in Chemistry, which included a strong focus on analytical chemistry. Subsequently he worked as a laboratory scientist in a GLP compliant research facility, progressing to Study Director. And, since 2010, he has been part of the clinical team at Waters (Wilmslow, UK). His principal focus has been on the development and validation of bioanalytical methods according to CLSI guidelines, with a focus on therapeutic drug monitoring. Additionally, he has supported newborn screening, vitamin and steroid analysis, including this clinical research method for free testosterone</blockquote>

Free Testosterone and Free T3/T4

Simplified Equilibrium Dialysis and SPE Method for the UPLC™-MS/MS Analysis of Free Thyroxine (FT4) and Triiodothyronine (FT3) for Clinical Research.

Host cell proteins (HCPs) are proteins that are produced by the host cells used in the production of biopharmaceuticals. These proteins can be impurities in the final product and due to their potential to adversely impact product safety and efficacy, HCP levels must be monitored and controlled in drug products and are strictly regulated.By employing advanced analytical techniques, biopharmaceutical companies can effectively monitor and control HCP levels, ensuring the production of safe and effective therapeutic products. Join us in this unique webinar where experts from Industry, pharmacopeia and Agilent will share insights on latest advancements on HCP analysis.Key learnings:<ul><li>Best practices for sample preparation, MS data acquisition, data analysis and reporting</li><li>Orthogonality of MS and traditional methods</li><li>USP approach for HCP reference materials to support identification and quantitation of HCPs</li><li>New advancements in detection and sensitivity</li><li>Process and analytical controls for host cell impurities</li><li>LC/MS based HCP identification approaches</li><li>Mandates on host specific HCP assays</li><li>and more</li></ul><blockquote>Presenter: Dr. Annu Uppal (Director - Scientific Affairs &amp; Strategy, U.S. Pharmacopeia - India)Annu Uppal, in her role as Director, Scientific Affairs and Strategy, leads a team of scientists across five regions—North America, EMEA, South Asia, Greater China, and LATAM—to drive and support USPs scientific priorities. Annu leads pivotal initiatives such as USP's Science &amp; Quality Framework and Knowledge Hubs for Multi-Attribute Methods, highlighting her dedication to advancing standards and scientific progress.Annu's areas of expertise include glycosylation analysis, MAM, native mode, and host cell protein analysis. She holds a Ph.D. in Biotechnology from Aligarh Muslim University, India and has authored numerous peer-reviewed manuscripts and book chapters. Annu also serves as faculty for the USP biologics education program on method development and validation.Presenter: Dr. Amarnath Chatterjee (Director and Head Analytical Sciences Biosimilars, Cipla Limited)Dr. Amarnath is a Biophysicist with more than two decades of experience working with peptides and proteins. Post PhD at the prestigious Tata Institute of Fundamental research, Mumbai, he worked at the Scripps Research Institute California, USA in the laboratory of Nobel Laureate Prof. Kurt Wuthrich. He has substantial experience in the regulatory role of Biophysics in the Biopharma industry.Dr. Amarnath leads the biologics development technical operations, providing expert advice on analytical workflows for quality control and characterization of client projects. He strategizes and supports the generation and analysis of physicochemical data under CMC, utilizing various spectrometric and spectroscopic methodologies for product release, regulatory submissions, and process developmentPresenter:&nbsp;Dr. Ashish Pargaonkar (Biopharma Workflow Commercialization Lead, Agilent Technologies)Dr. Ashish Pargaonkar is a Lead for Biopharma Workflow Commercialization team for India and also Manager for Centre of Excellences at Bangalore. A Microbiologist by education with a Ph.D, he holds more than 20 years of experience for Biopharma market applications on Hi Resolution Mass Spectrometry.He has a long record of successful demonstrations and customer engagements on workflows for CQA’s, Intact mass, peptide mapping, HCP and Glycans using Agilent state-of-the art solutions. He has authored ASMS posters on media components and therapeutic peptides. Dr. Ashish has been invited speaker at several conferences and workshops at Biosimilar Congress, ADC 2018, IIT (Mumbai, Delhi), ICT (Mumbai), PSI events.</blockquote>

Agilent: Advancements in Host Cell Protein Analysis

Advancements in Host Cell Protein Analysis

Experts from Industry, pharmacopeia and Agilent will share insights on latest advancements on HCP analysis.

Software can help streamline critical processes in therapeutic analysis, enhancing efficiency, ensuring compliance and maintaining product quality.This webinar explores how to implement digitization to accelerate decision-making, meet regulatory demands and eliminate bottlenecks in biotherapeutic development, helping to drive new therapeutics into the clinic. Attend this webinar to:<ul><li>Explore how analytical software can streamline and automate critical processes in therapeutic development</li><li>Understand how digital solutions can overcome bottlenecks in analytical testing</li><li>Discover best practices and strategies for harnessing the power of software</li></ul><blockquote>Presenter: Makesh Karpagavinayagam (Sr. Manager, Product Manager, at Thermo Fisher Scientific)Makesh Karpagavinayagam serves as the Senior Manager of Product Management at ThermoFisher Scientific, overseeing Rapid Microbial Identification and Software products that ensure the quality, safety and potency of pharmaceutical products. With over a decade of experience, Makesh has led product management teams, launched customer-centric products and collaborated with R&amp;D groups to provide high-quality genetic analysis solutions for applications in biopharma, forensics and academia.</blockquote>

Technology Networks: Streamlining Data for Superior Therapeutic Manufacturing

Streamlining Data for Superior Therapeutic Manufacturing

Explore how to implement digitization to accelerate decision-making, meet regulatory demands and eliminate bottlenecks in biotherapeutic development.